Data / Form D filings / MethylGene Inc.
MethylGene Inc.: Form D filings
MethylGene Inc., a biotechnology company in Montreal, Quebec, Canada, filed 4 Form D notices with the SEC between 2011 and 2012. The latest, on November 21, 2012, reports $26.1 million sold of a $35.5 million offering to 17 investors.
Find out what MethylGene Inc. does, who founded it and who invested, beyond what the filing says. $10 of credit on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 7150 FREDERICK BANTING STREET, SUITE 200, Montreal, Quebec, Canada, H4S 2
- Phone
- (514) 337-3333
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Canada (Federal Level)
- Revenue range
- $1,000,001 - $5,000,000
- Exemptions claimed
- Rule 506
- SEC identifier (CIK)
- 1516722
The full lists. Form D filings in Biotechnology: 1,568 rows, $78.40, or the new rows each week for $19 a month. Form D filings: 44,302 rows, $523.02, or the new rows each week for $92.05 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (company, CIK, year incorporated, street, city, state and 5 more), which open on your screen as soon as the payment clears and come by email. For agents and scripts: every list with its row count and price is at https://specstream.ai/data/lists.json.
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Nov 21, 2012 | New notice | $35,530,414 | $26,125,730 | $9,404,684 | 17 | Nov 9, 2012 | sec.gov |
| Nov 16, 2012 | Amendment | $48,270,612 | $35,556,560 | $12,714,052 | 20 | Mar 24, 2011 | sec.gov |
| Sep 11, 2012 | Amendment | $48,270,612 | $35,556,560 | $12,714,052 | 20 | Mar 24, 2011 | sec.gov |
| Apr 7, 2011 | New notice | $48,301,344 | $35,513,141 | $12,788,203 | 20 | Mar 24, 2011 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| GREGORY B. REID | Executive Officer | |
| HENRY J. FUCHS | Director | |
| KLAUS B. KEPPER | Executive Officer | |
| RACHEL B. HUMPHREY | Executive Officer | |
| RODNEY W. LAPPE | Director | |
| PETER W. THOMPSON | Director | |
| JOSEPH B. WALEWICZ | Executive Officer | |
| JEFFREY M. BESTERMAN | Executive Officer | |
| PEGGY W. MULLIGAN | Director | |
| MARTIN GODBOUT | Executive Officer, Director | |
| CHARLES W. BAUM | Executive Officer, Director | |
| ARKADII B. VAISBURG | Executive Officer |
Every Form D from the week of Nov 19, 2012 · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what MethylGene Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.
$10 of credit on sign-up, no card.